- Home
- OBE vs SIGA Comparison
OBE vs SIGA Comparison
Compare OBE & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBE
- SIGA
- Stock Information
- Founded
- OBE 1979
- SIGA 1995
- Country
- OBE Canada
- SIGA United States
- Employees
- OBE N/A
- SIGA N/A
- Industry
- OBE Oil & Gas Production
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- OBE Energy
- SIGA Health Care
- Exchange
- OBE Nasdaq
- SIGA Nasdaq
- Market Cap
- OBE 402.1M
- SIGA 443.4M
- IPO Year
- OBE N/A
- SIGA 1997
- Fundamental
- Price
- OBE $6.01
- SIGA $5.91
- Analyst Decision
- OBE Strong Buy
- SIGA
- Analyst Count
- OBE 1
- SIGA 0
- Target Price
- OBE $14.00
- SIGA N/A
- AVG Volume (30 Days)
- OBE 486.6K
- SIGA 401.8K
- Earning Date
- OBE 02-25-2025
- SIGA 03-11-2025
- Dividend Yield
- OBE N/A
- SIGA 10.16%
- EPS Growth
- OBE N/A
- SIGA N/A
- EPS
- OBE 1.05
- SIGA 1.20
- Revenue
- OBE $516,155,298.00
- SIGA $173,731,386.00
- Revenue This Year
- OBE $23.37
- SIGA $16.79
- Revenue Next Year
- OBE $5.83
- SIGA $15.08
- P/E Ratio
- OBE $5.19
- SIGA $4.94
- Revenue Growth
- OBE 3.06
- SIGA 399.31
- 52 Week Low
- OBE $4.87
- SIGA $4.75
- 52 Week High
- OBE $9.07
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- OBE 63.68
- SIGA 43.23
- Support Level
- OBE $5.25
- SIGA $5.80
- Resistance Level
- OBE $6.18
- SIGA $6.25
- Average True Range (ATR)
- OBE 0.24
- SIGA 0.23
- MACD
- OBE 0.09
- SIGA 0.01
- Stochastic Oscillator
- OBE 85.54
- SIGA 43.44
About OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Crude oil sale.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.